A Case of HLA-DRB1-MET Rearranged Lung Adenocarcinoma With Rapid Response to Crizotinib

Clin Lung Cancer. 2021 May;22(3):e298-e300. doi: 10.1016/j.cllc.2020.05.005. Epub 2020 Jun 12.
No abstract available

Keywords: Crizotinib; HLA-DRB1-MET rearrangement; MET fusions; Non–small-cell lung cancer; Targeted treatments.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma of Lung / drug therapy*
  • Adenocarcinoma of Lung / genetics
  • Adenocarcinoma of Lung / pathology
  • Crizotinib / administration & dosage*
  • Female
  • Gene Rearrangement
  • HLA-DRB1 Chains / genetics
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Middle Aged
  • Protein Kinase Inhibitors / administration & dosage*
  • Proto-Oncogene Proteins c-met / genetics
  • Treatment Outcome

Substances

  • HLA-DRB1 Chains
  • Protein Kinase Inhibitors
  • Crizotinib
  • MET protein, human
  • Proto-Oncogene Proteins c-met